Jason V Baker1, Katherine Huppler Hullsiek, Amrit Singh, Eleanor Wilson, Keith Henry, Ken Lichtenstein, Nur Onen, Erna Kojic, Pragna Patel, John T Brooks, Howard N Hodis, Matt Budoff, Irini Sereti. 1. aDepartment of Medicine, University of Minnesota bDivision of Infectious Diseases, Hennepin County Medical Center cDivision of Biostatistics, University of Minnesota, Minneapolis, Minnesota dNational Institute of Allergy and Infectious Disease (NIAID), NIH, Bethesda, Maryland eNational Jewish Medical and Research Center, Denver, Colorado fWashington University School of Medicine, St Louis, Missouri gMiriam Hospital, Providence, Rhode Island hDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia iAtherosclerosis Research Unit, University of Southern California jLos Angeles Biomedical Research Institute at Harbor-UCLA, Los Angeles, California, USA.
Abstract
BACKGROUND: Identifying immunologic mechanisms that contribute to premature cardiovascular disease (CVD) among HIV-positive patients will inform prevention strategies. METHODS: Coronary artery calcium (CAC) progression was studied in an HIV cohort. Immunophenotypes were measured on baseline cryopreserved peripheral blood mononuclear cells using multicolor flow cytometry. Logistic regression identified predictors of CAC progression after adjusting for traditional and HIV-related risk factors. RESULTS: Baseline characteristics for the analysis cohort (n=436) were median age 42 years, median CD4 cell count 481 cells/μl, and 78% receiving antiretroviral therapy. Higher frequencies of CD16 monocytes were associated with greater likelihood of CAC progression, after adjusting for traditional and HIV risk factors [odds ratio per doubling was 1.66 for CD14/CD16 (P=0.02), 1.36 for CD14/CD16 (P=0.06), and 1.69 for CD14/CD16 (P=0.01)]. Associations for CD16 monocytes persisted when restricted to participants with viral suppression. We found no significant associations for CAC progression with other cellular phenotypes, including T-cell activation and senescence markers. CONCLUSION: Circulating CD16 monocytes, potentially reflecting a more pro-atherogenic subpopulation, independently predicted greater CAC progression among HIV-infected persons at low risk for AIDS. In contrast to T-cell abnormalities classically associated with AIDS-related disease progression, these data highlight the potential role of monocyte activation in HIV-related CVD risk.
BACKGROUND: Identifying immunologic mechanisms that contribute to premature cardiovascular disease (CVD) among HIV-positivepatients will inform prevention strategies. METHODS: Coronary artery calcium (CAC) progression was studied in an HIV cohort. Immunophenotypes were measured on baseline cryopreserved peripheral blood mononuclear cells using multicolor flow cytometry. Logistic regression identified predictors of CAC progression after adjusting for traditional and HIV-related risk factors. RESULTS: Baseline characteristics for the analysis cohort (n=436) were median age 42 years, median CD4 cell count 481 cells/μl, and 78% receiving antiretroviral therapy. Higher frequencies of CD16 monocytes were associated with greater likelihood of CAC progression, after adjusting for traditional and HIV risk factors [odds ratio per doubling was 1.66 for CD14/CD16 (P=0.02), 1.36 for CD14/CD16 (P=0.06), and 1.69 for CD14/CD16 (P=0.01)]. Associations for CD16 monocytes persisted when restricted to participants with viral suppression. We found no significant associations for CAC progression with other cellular phenotypes, including T-cell activation and senescence markers. CONCLUSION: Circulating CD16 monocytes, potentially reflecting a more pro-atherogenic subpopulation, independently predicted greater CAC progression among HIV-infectedpersons at low risk for AIDS. In contrast to T-cell abnormalities classically associated with AIDS-related disease progression, these data highlight the potential role of monocyte activation in HIV-related CVD risk.
Authors: Tamar S Polonsky; Robyn L McClelland; Neal W Jorgensen; Diane E Bild; Gregory L Burke; Alan D Guerci; Philip Greenland Journal: JAMA Date: 2010-04-28 Impact factor: 56.272
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Amanda Mocroft; Peter Reiss; Jacek Gasiorowski; Bruno Ledergerber; Justyna Kowalska; Antonio Chiesi; Jose Gatell; Aza Rakhmanova; Margaret Johnson; Ole Kirk; Jens Lundgren Journal: J Acquir Immune Defic Syndr Date: 2010-10 Impact factor: 3.731
Authors: Virginia A Triant; Susan Regan; Hang Lee; Paul E Sax; James B Meigs; Steven K Grinspoon Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2007-04-26 Impact factor: 91.245
Authors: David A Zidar; Steven Juchnowski; Brian Ferrari; Brian Clagett; Heather A Pilch-Cooper; Shawn Rose; Benigno Rodriguez; Grace A McComsey; Scott F Sieg; Nehal N Mehta; Michael M Lederman; Nicholas T Funderburg Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Samir K Gupta; Ziyue Liu; Emily C Sims; Matthew J Repass; Laura S Haneline; Mervin C Yoder Journal: J Infect Dis Date: 2019-03-15 Impact factor: 5.226
Authors: Ahmed Tawakol; Amorina Ishai; Danny Li; Richard A P Takx; Sophia Hur; Yannick Kaiser; Miguel Pampaloni; Adam Rupert; Denise Hsu; Irini Sereti; Rémi Fromentin; Nicolas Chomont; Peter Ganz; Steven G Deeks; Priscilla Y Hsue Journal: JAMA Cardiol Date: 2017-02-01 Impact factor: 14.676
Authors: Alison G Abraham; Annie Darilay; Heather McKay; Joseph B Margolick; Michelle M Estrella; Frank J Palella; Robert Bolan; Charles R Rinaldo; Lisa P Jacobson Journal: J Infect Dis Date: 2015-03-11 Impact factor: 5.226
Authors: Eleanor M P Wilson; Amrit Singh; Katherine Huppler Hullsiek; Dave Gibson; W Keith Henry; Ken Lichtenstein; Nur F Önen; Erna Kojic; Pragna Patel; John T Brooks; Irini Sereti; Jason V Baker Journal: J Infect Dis Date: 2014-05-09 Impact factor: 5.226
Authors: Melissa E Schechter; Bruno B Andrade; Tianyu He; George Haret Richter; Kevin W Tosh; Benjamin B Policicchio; Amrit Singh; Kevin D Raehtz; Virginia Sheikh; Dongying Ma; Egidio Brocca-Cofano; Cristian Apetrei; Russel Tracy; Ruy M Ribeiro; Alan Sher; Ivo M B Francischetti; Ivona Pandrea; Irini Sereti Journal: Sci Transl Med Date: 2017-08-30 Impact factor: 17.956